These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Modulation of Regulatory T Cell Activity by TNF Receptor Type II-Targeting Pharmacological Agents. Zou H; Li R; Hu H; Hu Y; Chen X Front Immunol; 2018; 9():594. PubMed ID: 29632537 [TBL] [Abstract][Full Text] [Related]
23. Transmembrane TNF-α promotes suppressive activities of myeloid-derived suppressor cells via TNFR2. Hu X; Li B; Li X; Zhao X; Wan L; Lin G; Yu M; Wang J; Jiang X; Feng W; Qin Z; Yin B; Li Z J Immunol; 2014 Feb; 192(3):1320-31. PubMed ID: 24379122 [TBL] [Abstract][Full Text] [Related]
24. The imbalanced profile and clinical significance of T helper associated cytokines in bone marrow microenvironment of the patients with acute myeloid leukemia. Sun YX; Kong HL; Liu CF; Yu S; Tian T; Ma DX; Ji CY Hum Immunol; 2014 Feb; 75(2):113-8. PubMed ID: 24269703 [TBL] [Abstract][Full Text] [Related]
26. TNF-alpha: an activator of CD4+FoxP3+TNFR2+ regulatory T cells. Chen X; Oppenheim JJ Curr Dir Autoimmun; 2010; 11():119-34. PubMed ID: 20173391 [TBL] [Abstract][Full Text] [Related]
27. Cancer-testis antigen expression and its epigenetic modulation in acute myeloid leukemia. Atanackovic D; Luetkens T; Kloth B; Fuchs G; Cao Y; Hildebrandt Y; Meyer S; Bartels K; Reinhard H; Lajmi N; Hegewisch-Becker S; Schilling G; Platzbecker U; Kobbe G; Schroeder T; Bokemeyer C; Kröger N Am J Hematol; 2011 Nov; 86(11):918-22. PubMed ID: 21898529 [TBL] [Abstract][Full Text] [Related]
28. TNFR2 on non-haematopoietic cells is required for Foxp3+ Treg-cell function and disease suppression in EAE. Tsakiri N; Papadopoulos D; Denis MC; Mitsikostas DD; Kollias G Eur J Immunol; 2012 Feb; 42(2):403-12. PubMed ID: 22105853 [TBL] [Abstract][Full Text] [Related]
29. Pan-histone deacetylase inhibitor panobinostat depletes CXCR4 levels and signaling and exerts synergistic antimyeloid activity in combination with CXCR4 antagonists. Mandawat A; Fiskus W; Buckley KM; Robbins K; Rao R; Balusu R; Navenot JM; Wang ZX; Ustun C; Chong DG; Atadja P; Fujii N; Peiper SC; Bhalla K Blood; 2010 Dec; 116(24):5306-15. PubMed ID: 20810927 [TBL] [Abstract][Full Text] [Related]
30. Antileukemic T-cell responses can be predicted by the composition of specific regulatory T-cell subpopulations. Schick J; Vogt V; Zerwes M; Kroell T; Kraemer D; Köhne CH; Hausmann A; Buhmann R; Tischer J; Schmetzer H J Immunother; 2013 May; 36(4):223-37. PubMed ID: 23603857 [TBL] [Abstract][Full Text] [Related]
31. CD4+CD25+FOXP3+ T regulatory cells reconstitute and accumulate in the bone marrow of patients with multiple myeloma following allogeneic stem cell transplantation. Atanackovic D; Cao Y; Luetkens T; Panse J; Faltz C; Arfsten J; Bartels K; Wolschke C; Eiermann T; Zander AR; Fehse B; Bokemeyer C; Kroger N Haematologica; 2008 Mar; 93(3):423-30. PubMed ID: 18287134 [TBL] [Abstract][Full Text] [Related]
32. TNFR2-expressing CD4 He J; Li R; Chen Y; Hu Y; Chen X Prog Mol Biol Transl Sci; 2019; 164():101-117. PubMed ID: 31383403 [TBL] [Abstract][Full Text] [Related]
33. 5-Aza-2'-deoxycytidine (decitabine) can relieve p21WAF1 repression in human acute myeloid leukemia by a mechanism involving release of histone deacetylase 1 (HDAC1) without requiring p21WAF1 promoter demethylation. Scott SA; Dong WF; Ichinohasama R; Hirsch C; Sheridan D; Sanche SE; Geyer CR; Decoteau JF Leuk Res; 2006 Jan; 30(1):69-76. PubMed ID: 16043219 [TBL] [Abstract][Full Text] [Related]
34. Accumulation of TNFR2-expressing regulatory T cells in malignant pleural effusion of lung cancer patients is associated with poor prognosis. Ye LL; Peng WB; Niu YR; Xiang X; Wei XS; Wang ZH; Wang X; Zhang SY; Chen X; Zhou Q Ann Transl Med; 2020 Dec; 8(24):1647. PubMed ID: 33490159 [TBL] [Abstract][Full Text] [Related]
35. Panobinostat in lymphoid and myeloid malignancies. Khot A; Dickinson M; Prince HM Expert Opin Investig Drugs; 2013 Sep; 22(9):1211-23. PubMed ID: 23826641 [TBL] [Abstract][Full Text] [Related]
36. Impaired control of effector T cells by regulatory T cells: a clue to loss of oral tolerance and autoimmunity in celiac disease? Hmida NB; Ben Ahmed M; Moussa A; Rejeb MB; Said Y; Kourda N; Meresse B; Abdeladhim M; Louzir H; Cerf-Bensussan N Am J Gastroenterol; 2012 Apr; 107(4):604-11. PubMed ID: 22108452 [TBL] [Abstract][Full Text] [Related]
37. After Treatment Decrease of Bone Marrow Tregs and Outcome in Younger Patients with Newly Diagnosed Acute Myeloid Leukemia. Delia M; Carluccio P; Mestice A; Frappampina R; Albano F; Specchia G; Musto P J Immunol Res; 2020; 2020():2134647. PubMed ID: 33204734 [TBL] [Abstract][Full Text] [Related]
38. Natural but not inducible regulatory T cells require TNF-alpha signaling for in vivo function. Housley WJ; Adams CO; Nichols FC; Puddington L; Lingenheld EG; Zhu L; Rajan TV; Clark RB J Immunol; 2011 Jun; 186(12):6779-87. PubMed ID: 21572024 [TBL] [Abstract][Full Text] [Related]
39. The posttraumatic activation of CD4+ T regulatory cells is modulated by TNFR2- and TLR4-dependent pathways, but not by IL-10. Bock M; Bergmann CB; Jung S; Kalbitz M; Relja B; Huber-Wagner S; Biberthaler P; van Griensven M; Hanschen M Cell Immunol; 2018 Sep; 331():137-145. PubMed ID: 29954581 [TBL] [Abstract][Full Text] [Related]
40. Tremelimumab (anti-CTLA4) mediates immune responses mainly by direct activation of T effector cells rather than by affecting T regulatory cells. Khan S; Burt DJ; Ralph C; Thistlethwaite FC; Hawkins RE; Elkord E Clin Immunol; 2011 Jan; 138(1):85-96. PubMed ID: 21056008 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]